Peptide Clinical Trial Endpoints: Choosing Measures That Answer the Question

The best endpoint is not necessarily the most measurable variable. It is the measure that answers the clinical question with enough reliability and context to support interpretation. For peptide programs, teams may consider symptoms, function, biomarkers, imaging, pharmacokinetics, safety events, or patient-reported outcomes. Each has different collection burdens and different relationships to patient benefit.

Design before enrollment

Define the estimand: population, treatment condition, variable, handling of intercurrent events, and summary measure. Then specify timing, assessment method, training, acceptable windows, and missing-data rules. ICH E9(R1) and E6(R3) provide useful structure for separating the scientific question from the operational mechanics of answering it.

Endpoints should be feasible at participating sites. If a measure requires specialized equipment, lengthy training, or fragile sample handling, the protocol needs a realistic readiness plan. A research coordinator can track site training, assessment windows, query resolution, and data completeness without changing the endpoint’s scientific definition.

Evidence-first interpretation

Avoid treating a statistically different result as automatically clinically meaningful. Report effect size, uncertainty, baseline context, missingness, multiplicity, and the prespecified analysis. Patient-focused FDA resources also support asking whether the measure reflects an outcome people notice and value.

Scope note

This is trial-design education, not clinical advice or a recommendation for a particular endpoint.